Bloomberg strategist warns Ether could slide toward $2K
A Bloomberg Intelligence strategist has warned Ether is more likely to fall toward $2,000 than recover to $4,000 amid macro and cross-asset pressures.
Todas as matérias desta categoria, das mais recentes às mais antigas.
A Bloomberg Intelligence strategist has warned Ether is more likely to fall toward $2,000 than recover to $4,000 amid macro and cross-asset pressures.
Crypto exchange-traded products shed $446 million over Christmas, as investors stayed cautious and rotated into newer XRP and Solana funds.
China will allow banks to pay interest on digital yuan wallets from 2026, signalling a shift toward treating the e-CNY as deposit-like money.
XRP, Zcash and Algorand defied a weak altcoin market in 2025, rebounding on regulatory clarity, privacy demand and real-world tokenisation.
Web3 losses surged to nearly $4 billion in 2025, with Hacken blaming weak key security and North Korea-linked attackers for most of the damage.
Real-world asset protocols have overtaken decentralised exchanges by total value locked, signalling their rise as a core category within decentralised finance.
BlackRock’s BUIDL tokenised money market fund has paid out $100 million in Treasury yield dividends, highlighting institutional adoption of onchain finance.
Strategy has completed its latest Bitcoin purchase of 2025, lifting total holdings to 672,497 BTC after a year of aggressive corporate accumulation.
A South Korean lawmaker is facing scrutiny after reports alleged he sought to help his son secure a job at a crypto exchange while questioning a rival firm.
Delixy Holdings (NASDAQ:DLXY) reported a contraction in top-line growth for the first six months of 2025, as the recently listed oil trader navigated a volatile energy market and narrowed its focus toward higher-margin operations.
California Water Service (NYSE:CWT) will implement a 3% interim rate increase across most of its districts starting Jan. 1, after state regulators authorized the temporary measure to bridge a delay in the utility’s broader triennial rate review.
ARS Pharmaceuticals (NASDAQ:SPRY) said China’s drug regulator has approved neffy 2 mg, an epinephrine nasal spray, for the emergency treatment of Type 1 allergic reactions in adults and children weighing at least 30 kilograms, marking the first epinephrine product authorized for community use in the country.
Tem um segundo para um cookie? 🍪Os cookies essenciais mantêm a Grafa funcionando bem. Alguns opcionais nos ajudam a ver o que está funcionando para melhorarmos. Você tem o controle — pode mudar de ideia quando quiser. Política de cookies · Política de privacidade